Total Assets (Quarterly) Chart

View Total Assets (Quarterly) for PAIOF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Assets (Quarterly) Chart
Start Trial

Historical Total Assets (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
December 31, 2015 47.22M
September 30, 2015 55.01M
June 30, 2015 63.48M
March 31, 2015 66.93M
December 31, 2014 80.53M
September 30, 2014 85.93M
June 30, 2014 33.73M
March 31, 2014 35.28M
December 31, 2013 24.83M
September 30, 2013 23.32M
June 30, 2013 23.93M
March 31, 2013 34.24M
December 31, 2012 37.36M
September 30, 2012 36.12M
June 30, 2012 35.85M
March 31, 2012 40.46M
December 31, 2011 16.36M
September 30, 2011 28.30M
June 30, 2011 33.25M
March 31, 2011 34.14M
December 31, 2010 36.00M
September 30, 2010 37.39M
June 30, 2010 38.40M
Date Value
March 31, 2010 43.48M
December 31, 2009 51.01M
September 30, 2009 57.05M
June 30, 2009 60.49M
March 31, 2009 60.61M
December 31, 2008 68.55M
September 30, 2008 84.33M
June 30, 2008 107.16M
March 31, 2008 81.80M
December 31, 2007 66.58M
September 30, 2007 68.94M
June 30, 2007 82.43M
March 31, 2007 89.25M
December 31, 2006 92.37M
September 30, 2006 92.52M
June 30, 2006 91.90M
March 31, 2006 72.83M
December 31, 2005 78.03M
September 30, 2005 83.95M
June 30, 2005 71.43M
March 31, 2005 81.57M
December 31, 2004
September 30, 2004 35.58M

Total Assets Definition

Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.

Read full definition.

Total Assets (Quarterly) Range, Past 5 Years

View Total Assets (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Assets (Quarterly) Benchmarks

View Total Assets (Quarterly) Benchmarks
Start Trial
CureVac NV 1.338B
Anbio Biotechnology --
Epigenomics AG --
ACADIA Pharmaceuticals, Inc. 1.743B
Alkermes Plc 4.393B